Expertise in
5
conditions

Kassim M. Javaid

Oxford, ENG, GB 
Expertise in
5
conditions
Oxford, ENG, GB 
OverviewLocationsClinical Research

Overview

Kassim Javaid practices in Oxford, United Kingdom. Mr. Javaid is highly rated in 5 conditions, according to our data. His top areas of expertise are Osteoporosis, Osteoarthritis, Rickets, and Osteomalacia.

His clinical research consists of co-authoring 21 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Oxford, ENG, United Kingdom
Other Locations
Falls And Fragility Audit Programme, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Treatment of Osteogenesis Imperfecta With Parathyroid Hormone and Zoledronic Acid
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drugs: Teriparatide, Zoledronic Acid
Study Phase: Phase 4
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
A Phase 2b, Multicentre, Multinational, Double-blind, Dose-finding Study, Incorporating an Open Label Substudy, in Adult Patients With Type I, III or IV Osteogenesis Imperfecta Treated With Setrusumab (BPS804)
Enrollment Status: Completed
Publish Date: July 05, 2023
Intervention Type: Dietary supplement, Drug
Study Phase: Phase 2
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
A Phase 3b Open-label Study of the Anti-FGF23 Antibody, Burosumab (KRN23) in Adult Patients With X-linked Hypophosphatemia (XLH)
Enrollment Status: Completed
Publish Date: May 20, 2022
Intervention Type: Drug
Study Drug: Burosumab
Study Phase: Phase 3
View 2 Less Clinical Trials

21 Total Publications

Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Publisher Correction: Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia.
Journal: Nature reviews. Nephrology
Published: February 05, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Javaid's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile